Solantra cream 10mg/g 30 g — Made in France — Free Delivery

Cream "Solantra®" is used for the topical treatment of inflammatory lesions caused by rosacea (papular-pustular form) in adult patients.

The active substance is ivermectin (1 g of cream contains ivermectin 10 mg).

Auxiliary substances: glycerin; isopropyl palmitate; carbomeric copolymer type B; dimethicone 20 Cst; disodium edetate; citric acid monohydrate; cetyl alcohol; stearyl alcohol; macrogol cetostearyl ether; sorbitan stearate; methyl parahydroxybenzoate (E 218); propyl parahydroxybenzoate (E 216); phenoxyethanol; propylene glycol; oleyl alcohol; sodium hydroxide; purified water.

Hypersensitivity to the active substance or to any of the excipients of the preparation.

Cream "Solantra®" is used only on the skin of the face.

Apply a small amount of the preparation  (the size of a pea) to the skin on each of the five areas of the face: forehead, chin, nose and both cheeks. Spread the preparation in a thin layer over the skin of the entire face, avoiding the area of ​​​​the eyes, lips and mucous membranes.

Wash your hands after applying Solantra® cream.

Cosmetics can be applied only after the cream has dried.

Apply the cream 1 time per day daily for no more than 4 months. The course of treatment can be repeated.

If there is no improvement after 3 months, treatment should be discontinued.

Separate groups of patients:

impaired renal function - dose adjustment is not required;

impaired liver function - use with caution in patients with severe hepatic insufficiency;

elderly patients - for the geriatric patient population, dose adjustment is not required.

There is no or limited information on topical use of ivermectin in pregnant women. Reproductive toxicity studies with oral ivermectin have demonstrated that ivermectin is teratogenic in animals, however, due to the low systemic exposure of the substance after topical application at the recommended dosage, the likelihood of damage to human embryos is low. Cream "Solantra®" is not recommended for use during pregnancy.

Following oral administration, low concentrations of ivermectin are excreted in breast milk. Excretion into breast milk after topical application has not been studied. Available pharmacokinetic/toxicological data in animals also indicate excretion of ivermectin into breast milk. A risk to the infant during breastfeeding cannot be ruled out. It is necessary to make a decision to stop breastfeeding or cancel / refuse treatment with Solantra® cream, weighing the benefits of breastfeeding for the child and the benefits of treatment for the woman.

There are no data on the effect of ivermectin on reproductive function in humans. In animals, there is no effect on mating or fertility during treatment with ivermectin.

The safety and efficacy of Solantra® cream in children (under 18 years of age) have not been studied. No data available.

Cream "Solantra®" does not affect or has a slight effect on the ability to drive vehicles and work with other mechanisms.

No cases of overdose of Solantra® cream have been reported.

In case of accidental ingestion of the preparation, supportive therapy is carried out, which, if indicated, may include parenteral fluid and electrolytes, respiratory support (if necessary, oxygen and mechanical ventilation), and pressor preparations in the presence of clinically significant hypotension. If necessary, to prevent absorption of the ingested substance, as soon as possible, artificially induce vomiting and / or perform gastric lavage, use laxatives and take other measures typical of poisoning.

The most common adverse reactions include burning sensation on the skin, skin irritation and dry skin. These events occurred in ≤ 1% of patients treated with this agent in clinical studies.

Does not require special storage conditions. Keep out of the reach of children.

Shelf life - 2 years.

After the first opening of the tube, the preparation  is suitable for use within 6 months.